REPURPOSED SIMVASTATIN-LOADED NANOSTRUCTURED LIPID CARRIERS: OPTIMIZATION, CHARACTERIZATION AND EVALUATION AGAINST LUNG CANCER
Open Access
- 7 July 2025
- journal article
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 497-510
Abstract
Objective: Repurposed Simvastatin (SMV) is being investigated for the treatment of lung malignancies. However, its inadequate solubility in water and formulation constraints are the potential challenges for its use against lung cancer. This study aimed at synthesis of SMV-loaded Nanostructured Lipid Carriers (SMV-NLC) for lung cancer management. Methods: Emulsification and probe sonication approach was chosen for the formulation of NLCs. A three-factor, three-level Box-Behnken design was utilized for the development of SMV-NLC formulation. The independent variables selected were total lipid concentration (%w/w), solid lipid: liquid lipid ratio, and surfactant concentration (%w/w). Screening of components was performed based on SMV solubility and SMV-excipient compatibility studies. Results: Optimized SMV-NLC showed a particle size of 209.8±1.8 nm, low polydispersity index (0.319±0.14), negative zeta potential (-20.35 mV) and good entrapment efficiency (73.51±4.22%). Transmission electron microscopy examination revealed spherical shape of NLC with validation of nanometric size. Fourier Transform Infrared analysis revealed the entrapment of the SMV within the lipid matrix of NLC. SMV release of 86.97±1.7% was obtained from NLC after 24 h with sustained release characteristics. In vitro cytotoxic activity against A549 cell lines (lung cancer) showed IC50of 11.34±0.12 and 30.26±0.14 µg/ml for SMV-NLC and SMV-suspension, respectively. Conclusion: The developed SMV-NLC may be utilized as an effective platform for the management of lung cancer.Keywords
This publication has 84 references indexed in Scilit:
- Statins as anti‐tumor agents: A paradigm for repurposed drugsCancer Reports, 2024
- Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulationMedical Oncology, 2024
- Drug repurposing—an emerging strategy in cancer therapeuticsNaunyn-Schmiedeberg's Archives of Pharmacology, 2022
- Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancerDrug Delivery and Translational Research, 2020
- Noscapine‐Loaded Nanostructured Lipid Carriers as a Potential Topical Delivery to Bovine Mastitis TreatmentChemistrySelect, 2020
- Surface modification of lipid-based nanocarriers for cancer cell-specific drug targetingJournal of Pharmaceutical Investigation, 2017
- Role of Excipients in formulation development and biocompatibility of lipid nanoparticles (SLNs/NLCs)2017
- Cell Sensitivity Assays: The MTT Assay2011
- The controlled delivery of drugs to the lungInternational Journal of Pharmaceutics, 1995
- Long-term safety and efficacy profile of simvastatinThe American Journal of Cardiology, 1991